No Data
Castle Biosciences Is Maintained at Sector Outperform by Scotiabank
Scotiabank Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $44
Use of Castle Biosciences' DecisionDx-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings From Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
Castle Biosciences Third Quarter 2024 Earnings: Beats Expectations
Castle Biosciences Price Target Raised to $36 From $28 at KeyBanc
Strong Growth Prospects and Financial Health Support Buy Rating for Castle Biosciences
No Data
No Data